These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 20072836

  • 1. Decitabine.
    Daskalakis M, Blagitko-Dorfs N, Hackanson B.
    Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
    [Abstract] [Full Text] [Related]

  • 2. Decitabine.
    Hackanson B, Daskalakis M.
    Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
    [Abstract] [Full Text] [Related]

  • 3. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
    Cowan LA, Talwar S, Yang AS.
    Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
    [Abstract] [Full Text] [Related]

  • 4. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH.
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [Abstract] [Full Text] [Related]

  • 5. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG, Nagler A.
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [Abstract] [Full Text] [Related]

  • 6. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR.
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [Abstract] [Full Text] [Related]

  • 7. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
    Fenaux P.
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
    [Abstract] [Full Text] [Related]

  • 8. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L, Greil R.
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [Abstract] [Full Text] [Related]

  • 9. Decitabine in myelodysplastic syndromes.
    Saba HI, Wijermans PW.
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [Abstract] [Full Text] [Related]

  • 10. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B, Robbel C, Wijermans P, Lübbert M.
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [Abstract] [Full Text] [Related]

  • 11. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A, Santini V.
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [Abstract] [Full Text] [Related]

  • 12. Decitabine and its role in the treatment of hematopoietic malignancies.
    Plimack ER, Kantarjian HM, Issa JP.
    Leuk Lymphoma; 2007 Aug; 48(8):1472-81. PubMed ID: 17701577
    [Abstract] [Full Text] [Related]

  • 13. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
    Lübbert M.
    Curr Top Microbiol Immunol; 2000 Aug; 249():135-64. PubMed ID: 10802943
    [No Abstract] [Full Text] [Related]

  • 14. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C, Hackanson B, Stresemann C, Lübbert M, Lyko F.
    Cancer Res; 2005 Aug 15; 65(16):7086-90. PubMed ID: 16103056
    [Abstract] [Full Text] [Related]

  • 15. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN, Taverna P, Issa JP.
    Epigenomics; 2015 Oct 15; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract] [Full Text] [Related]

  • 16. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA, Dong WF, Ichinohasama R, Hirsch C, Sheridan D, Sanche SE, Geyer CR, Decoteau JF.
    Leuk Res; 2006 Jan 15; 30(1):69-76. PubMed ID: 16043219
    [Abstract] [Full Text] [Related]

  • 17. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE, Lübbert M.
    Semin Hematol; 2012 Oct 15; 49(4):330-41. PubMed ID: 23079063
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA.
    Best Pract Res Clin Haematol; 2013 Sep 15; 26(3):275-8. PubMed ID: 24309530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.